ArticleScientific reports2016
Deficiency of AXL in Bone Marrow-Derived Cells Does Not Affect Advanced Atherosclerotic Lesion Progression.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Efferocytosis induces macrophage proliferation to help resolve tissue injury.Cell metabolism · 2021Article
- Phosphatidylserine receptors enhance SARS-CoV-2 infection.PLoS pathogens · 2021Article
- Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction.The Journal of clinical investigation · 2021Article
- ODC (Ornithine Decarboxylase)-Dependent Putrescine Synthesis Maintains MerTK (MER Tyrosine-Protein Kinase) Expression to Drive Resolution.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- TAM receptors and their ligand-mediated activation: Role in atherosclerosis.International review of cell and molecular biology · 2020Review
- TAM receptors in cardiovascular disease.Cardiovascular research · 2019Review
- Antagonistic Coevolution of MER Tyrosine Kinase Expression and Function.Molecular biology and evolution · 2017Article
- The many ways tissue phagocytes respond to dying cells.Immunological reviews · 2017Review
- Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis.Frontiers in cardiovascular medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
AXL, a member of the TAM (Tyro3, Axl, MerTK) family of receptors, plays important roles in cell survival, clearance of dead cells (efferocytosis), and suppression of inflammation, which are processes that critically influence atherosclerosis progression. Whereas MerTK deficiency promotes defective efferocytosis, inflammation, and plaque necrosis in advanced murine atherosclerosis, the role of Axl in advanced atherosclerosis progression is not known. Towards this end, bone marrow cells from Axl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.